STOCK TITAN
  1. Home
  2. News
  3. TXG

10X Genomics, Inc. - TXG STOCK NEWS

Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.

10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.

Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.

Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.

Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.

News

10x Genomics Launches Xenium Catalyst Network

Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) launches Xenium Catalyst Network with 4 founding members to accelerate access to proof-of-concept data for prospective customers worldwide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
News

Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness

Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) published a study in Nature Communications using its industry-leading platforms to analyze human breast tumor microenvironments, showcasing the power of integrating findings and the value of spatial profiling techniques.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
-
News

High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint

Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) announced that the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 FFPE tissues compared to NanoString's CosMx and Vizgen's MERSCOPE in a new comparison study. Xenium showed higher sensitivity, on-target calls, and lower false discovery rate, as well as better correlation with reference RNA sequencing data. The platform also accurately measured low-expressing genes, exhibited a distinct tissue marker expression pattern, and performed well at distinguishing cells of distinct lineage and identifying all known cell types from breast and lung tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
none
News

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

Rhea-AI Summary
10x Genomics, Inc. (TXG) collaborates with NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a comprehensive single cell atlas of the human brain. The collaboration aims to further neuroscience research by profiling the epigenome and whole transcriptome across millions of individual cells from diverse brain samples. The goal is to provide a detailed genetic map of the damage caused in neurodegenerative disorders, facilitating the development of new treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
-
News

Curio Bioscience Responds to Lawsuit

Rhea-AI Summary
Curio Bioscience (CURIO) is a leading innovator in the life sciences industry, offering high-precision tools. Their Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution. The company is facing litigation from 10x Genomics (TXG) but is confident in their defense against patent infringement allegations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
News

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

Rhea-AI Summary
10x Genomics (TXG) Wins Patent Infringement Case Against NanoString, Awarded Over $31 Million in Damages: A jury in the U.S. District Court for the District of Delaware unanimously ruled in favor of 10x Genomics in the patent infringement suit against NanoString, awarding over $31 million in damages for willful infringement of seven patents. The ruling is the third against NanoString in six months, confirming serial infringement of 10x patents. Post-trial, 10x intends to seek ongoing royalties, treble damages, attorney's fees, a permanent injunction, and pre- and post-judgment interest. 10x's Chief Legal Officer emphasized the importance of protecting patents and thanked the jury for recognizing 10x's innovation. The ruling is based on extensive evidence, including testimony from key figures. This case is part of a larger legal battle, with another suit pending against NanoString in the U.S. District Court for the District of Delaware.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
News

OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study

Rhea-AI Summary
OWKIN and 10x Genomics have entered into an agreement to incorporate 10x Genomics' spatial omics and single-cell technologies into the MOSAIC project. MOSAIC is a $50 million project that utilizes spatial omics technologies to map tumor structures at single-cell resolution. With the addition of 10x Genomics' Visium technology and Chromium portfolio, MOSAIC aims to unlock transformative discoveries in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News

10x Genomics Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
10x Genomics reports Q3 2023 financial results with revenue of $153.6 million, a 17% increase YoY. Gross margin was 62%, operating expenses increased by 35%, and operating loss was $94.8 million. Net loss was $93.0 million. Cash and cash equivalents were $356.9 million. Full year 2023 revenue guidance raised to $610 million to $625 million, representing 18% to 21% growth over 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
earnings
-
News

10x Genomics to Present at the Stephens 25th Annual Conference

Rhea-AI Summary
10x Genomics, Inc. will participate in a fireside chat at the Stephens 25th Annual Conference on November 14, 2023. The live webcast can be accessed on the company's website and will be available for replay for 45 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.44%
Tags
conferences
News

Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

Rhea-AI Summary
10x Genomics announces the use of the 10x Xenium Analyzer in a study characterizing radiation-resistance mechanisms of diffuse midline gliomas. The study provides insights into clinical response and therapeutic strategies, revealing key transcriptomic changes and cell communication pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
Stock TXG logo
10X Genomics, Inc.

Nasdaq:TXG

TXG Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

TXG Stock Data

924.73M
106.05M
2.14%
96.93%
11.26%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON